We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Cross-Linked Implants Reduce Revision Surgery Rates

By HospiMedica International staff writers
Posted on 13 Aug 2018
A long-term follow-up study confirms that hip implants made of cross-linked polyethylene (XLPE) substantially lower the risk of revision surgery after total hip replacement.

Researchers at the South Australian Health and Medical Research Institute (SAHMRI; Adelaide, Australia) and the University of Adelaide (UA; Australia) conducted an observational study of all patients who underwent THA for osteoarthritis (OA) in Australia from 1999 through December 31, 2016, in order to compare total hip arthroplasty (THA) revision surgery rates between patients that received XLPE implants and those that received conventional non-cross-linked polyethylene (CPE) at 16 years follow up.

The data, extracted from the Australian Orthopaedic Association (Sydney, Australia) national joint replacement registry, revealed that CPE was used in 41,171 procedures, and XLPE was used in 199,131; men and women who received XLPE implants were slightly younger than those that underwent CPE. More...
XLPE implants were associated with a lower rate of revision at six months, with the difference becoming more apparent over time. The 16-year cumulative percentage of revisions of primary THAs was 11.7% in the CPE group and 6.2% in the XLPE group.

After adjustment for other risk factors, patients with CPE implants were about three times more likely to have revision surgery after nine years, compared to those with XLPE implants. At seven years, younger patients with CPE hip prostheses were about five times more likely to need revision surgery. Revisions directly related to wear of the bearing surface occurred in 0.81% of procedures that used CPE, compared to just 0.05% of procedures that used XLPE. The study was published on August 1, 2018, in The Journal of Bone & Joint Surgery.

“Wear-related and implant-longevity issues are particularly important in younger patients, who are generally more active and have a longer life span than their older counterparts,” concluded Professor Richard de Steiger, MD, of SAHMRI, and colleagues. “We believe that the evidence of reduced long-term wear with XLPE is now so strong that, when a polyethylene bearing surface is used in THA, it should be XLPE, particularly in younger patients."

THA is one of the most effective surgical procedures for the management of hip OA. The most common bearing surface for THA has been conventional CPE, which has been in use for over 50 years. As limiting wear of the bearing surface is critical to long-term success, particularly for younger patients, research has led to the development of XLPE, which has improved wear characteristics.

Related Links:
South Australian Health and Medical Research Institute
University of Adelaide
Australian Orthopaedic Association


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.